Edward Robert Scheffer Cliff (Edward R Scheffer Cliff, Edward R S Cliff, Edward R Scheffer Cliff)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 43

Top Topics

Systematic Review

Acute Lymphoblastic Leukemia

Multiple Myeloma

Top Venues

Blood cancer journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Ramya Ramachandran, Darshi Shah, Catherine Luo, Veer Shah, Edward Robert Scheffer Cliff, Vaishali Sanchorawala, Suzanne Lentzsch, Rajshekhar Chakraborty
The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. Blood advances 8 (13) (2024)
Gemma K Reynolds, Marsali Maclean, Edward Robert Scheffer Cliff, Benjamin W Teh, Karin A Thursky, Monica A Slavin, Mary Ann Anderson, Eliza A Hawkes
Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood advances 8 (13) (2024)
David M Cordas Dos Santos, Tobias Tix, Roni Shouval, Anat Gafter-Gvili, Jean-Baptiste Alberge, Edward Robert Scheffer Cliff, Sebastian Theurich, Michael von Bergwelt-Baildon, Irene M Ghobrial, Marion Subklewe, Miguel-Ángel Perales, Marion Subklewe
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nature medicine (2024)
Shin Hnin Wai, Sze Ting Lee, Edward Robert Scheffer Cliff, Michael Bei, Jiwoo Lee, Eliza A Hawkes, Geoffrey Chong
Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma. Blood advances 8 (3) (2024)
Ramya Ramachandran, Darshi Shah, Catherine Luo, Veer Shah, Edward Robert Scheffer Cliff, Vaishali Sanchorawala, Suzanne Lentzsch, Rajshekhar Chakraborty
The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. Blood advances 8 (13) (2024)
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina D Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D'Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin F Kaiser, Melissa Ng Liet Hing, Simon James Harrison, Edward Robert Scheffer Cliff, Meera Mohan
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood cancer journal 14 (1) (2024)
Ramya Ramachandran, Darshi Shah, Catherine Luo, Veer Shah, Edward Robert Scheffer Cliff, Vaishali Sanchorawala, Suzanne Lentzsch, Rajshekhar Chakraborty
The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. Blood advances 8 (13) (2024)
Shin Hnin Wai, Sze Ting Lee, Edward Robert Scheffer Cliff, Michael Bei, Jiwoo Lee, Eliza A Hawkes, Geoffrey Chong
Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma. Blood advances 8 (3) (2024)
Nosakhare Paul Ilerhunmwuwa, Abul Hasan Shadali Abdul Khader, Calvin Smith, Edward Robert Scheffer Cliff, Christopher M Booth, Evevanne Hottel, Muhammad Aziz, Wade Lee-Smith, Aaron Goodman, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin
Dietary interventions in cancer: a systematic review of all randomized controlled trials. Journal of the National Cancer Institute 116 (7) (2024)
Nosakhare Paul Ilerhunmwuwa, Abul Hasan Shadali Abdul Khader, Calvin Smith, Edward Robert Scheffer Cliff, Christopher M Booth, Evevanne Hottel, Muhammad Aziz, Wade Lee-Smith, Aaron Goodman, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin
Dietary interventions in cancer: a systematic review of all randomized controlled trials. Journal of the National Cancer Institute 116 (7) (2024)
Apoorva Kakkilaya, Aaron Trando, Edward Robert Scheffer Cliff, Hira Mian, Samer Al Hadidi, Muhammad Aziz, Aaron M Goodman, Ah-Reum Jeong, Wade L Smith, Amar H Kelkar, David A Russler-Germain, Nikita Mehra, Rajshekhar Chakraborty, Morie A Gertz, Ghulam Rehman Mohyuddin
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. The oncologist (2024)
Gemma Reynolds, Marsali Maclean, Edward Robert Scheffer Cliff, Benjamin W Teh, Karin A Thursky, Monica A Slavin, Mary Ann Anderson, Eliza A Hawkes
Infections in lymphoma patients treated with bispecific antibodies: A systematic review and meta-analysis. Blood advances (2024)
Edward Robert Scheffer Cliff, David A Russler-Germain, C Joseph Ross Daval, Aaron S Kesselheim
US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Gemma K Reynolds, Marsali Maclean, Edward Robert Scheffer Cliff, Benjamin W Teh, Karin A Thursky, Monica A Slavin, Mary Ann Anderson, Eliza A Hawkes
Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood advances 8 (13) (2024)
Gemma K Reynolds, Marsali Maclean, Edward Robert Scheffer Cliff, Benjamin W Teh, Karin A Thursky, Monica A Slavin, Mary Ann Anderson, Eliza A Hawkes
Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood advances 8 (13) (2024)
Ramya Ramachandran, Darshi Shah, Catherine Luo, Veer Shah, Edward Robert Scheffer Cliff, Vaishali Sanchorawala, Suzanne Lentzsch, Rajshekhar Chakraborty
The Clinical Trials Landscape in Immunoglobulin Light Chain Amyloidosis: A Systematic Review. Blood advances (2024)
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina D Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D'Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin F Kaiser, Melissa Ng Liet Hing, Simon James Harrison, Edward Robert Scheffer Cliff, Meera Mohan
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood cancer journal 14 (1) (2024)
Tobias Tix, Mohammad Alhomoud, Roni Shouval, Edward Robert Scheffer Cliff, Miguel-Ángel Perales, David M Cordas Dos Santos, Marion Subklewe
Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina D Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D'Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin F Kaiser, Melissa Ng Liet Hing, Simon James Harrison, Edward Robert Scheffer Cliff, Meera Mohan
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood cancer journal 14 (1) (2024)
David M Cordas Dos Santos, Tobias Tix, Roni Shouval, Anat Gafter-Gvili, Jean-Baptiste Alberge, Edward Robert Scheffer Cliff, Sebastian Theurich, Michael von Bergwelt-Baildon, Irene M Ghobrial, Marion Subklewe, Miguel-Ángel Perales, Marion Subklewe
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nature medicine (2024)
Shin Hnin Wai, Sze Ting Lee, Edward Robert Scheffer Cliff, Michael Bei, Jiwoo Lee, Eliza A Hawkes, Geoffrey Chong
Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma. Blood advances 8 (3) (2024)
Edward Robert Scheffer Cliff, Gemma Reynolds, Rakesh Popat, Benjamin W Teh, Aaron S Kesselheim, Ghulam Rehman Mohyuddin
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Edward Robert Scheffer Cliff, Aaron S Kesselheim, William B Feldman
Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Amar H Kelkar, Edward Robert Scheffer Cliff, Caron A Jacobson, Gregory A Abel, Stijntje Willemijn Dijk, Eline M Krijkamp, Robert A Redd, Joanna C Zurko, Mehdi Hamadani, M G Myriam Hunink, Corey S Cutler
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis. Annals of internal medicine (2023)
Edward Robert Scheffer Cliff, Amar H Kelkar, David A Russler-Germain, Frazer A Tessema, Adam J N Raymakers, William B Feldman, Aaron S Kesselheim
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 43 (2023)
Shin Hnin Wai, Sze-Ting Lee, Edward Robert Scheffer Cliff, Michael Bei, Jiwoo Lee, Eliza A Hawkes, Geoffrey Chong
Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma. Blood advances (2023)
Rajshekhar Chakraborty, Samer Al Hadidi, Edward Robert Scheffer Cliff, Ghulam Rehman Mohyuddin
Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood advances (2023)
Thomas E Lew, Edward Robert Scheffer Cliff, Michael J Dickinson, Constantine S Tam, John Francis Seymour, Piers A Blombery, Ashish Bajel, David S Ritchie, Amit Khot
Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease. Leukemia & lymphoma (2023)
Gemma Reynolds, Edward Robert Scheffer Cliff, Ghulam Rehman Mohyuddin, Rakesh Popat, Shonali Midha, Melissa Ng Liet Hing, Simon James Harrison, Aaron Kesselheim, Benjamin W Teh
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood advances (2023)
Edward Robert Scheffer Cliff, Talal Hilal, Aaron S Kesselheim
Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma. Nature reviews. Clinical oncology (2023)
David A Russler-Germain, Edward Robert Scheffer Cliff, Nancy L Bartlett
Cell-of-Origin Effect of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma: No Ordinary Subgroup Analysis. Blood (2023)
Edward Robert Scheffer Cliff, Ankur Pandya
Pola-R-CHP for DLBCL: cost-effective at first glance. Blood 140 (25) (2022)
Edward Robert Scheffer Cliff, Ankur Pandya
Pola-R-CHP for DLBCL: cost-effective at first glance. Blood 140 (25) (2022)
Edward Robert Scheffer Cliff, Ankur Pandya
Pola-R-CHP for DLBCL: cost-effective at first glance. Blood 140 (25) (2022)
Edward Robert Scheffer Cliff, Ghulam Rehman Mohyuddin
Overall survival as a primary end point in multiple myeloma trials. Nature reviews. Clinical oncology 19 (9) (2022)
Ajay Major, Edward Robert Scheffer Cliff, Daniel A Ermann, Urshila Durani, David A Russler-Germain
Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions. EJHaem 3 (3) (2022)
Edward Robert Scheffer Cliff, Ankur Pandya
Pola-R-CHP for DLBCL: cost-effective at first glance. Blood 140 (25) (2022)
Edward Robert Scheffer Cliff, Ankur Pandya
Pola-R-CHP for DLBCL: cost-effective at first glance. Blood 140 (25) (2022)
Oliver Van Oekelen, Nicole Birrer, William Wesson, Vincent L Galate, Edward Robert Scheffer Cliff, Aaron M Goodman, Al-Ola Abdallah, Rajshekhar Chakraborty, Vinay Prasad, Ghulam Rehman Mohyuddin
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. Blood cancer journal 12 (11) (2022)
Edward Robert Scheffer Cliff, Reid W Merryman, Philippe Armand, Caron A Jacobson
Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma. Nature medicine (2022)
Edward Robert Scheffer Cliff, Joe Sasadeusz, Kumar Visvanathan, Andrew Grigg
Very late-onset hepatitis B reactivation following chemoimmunotherapy. Leukemia & lymphoma (2021)
Edward Robert Scheffer Cliff, Jeffrey Szer
We must grow the Australian Bone Marrow Donor Registry. Internal medicine journal 51 (11) (2021)
Thomas E Lew, Edward Robert Scheffer Cliff, Michael Dickinson, Constantine S Tam, John Francis Seymour, Piers Blombery, Ashish Bajel, David Ritchie, Amit Khot
T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. Bone marrow transplantation 56 (11) (2021)